Moleculin Biotech, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Moleculin Biotech completed enrollment of 89 subjects in Part A of its pivotal MIRACLE Phase 2/3 trial evaluating Annamycin plus cytarabine for relapsed/refractory AML. The company remains on track for comprehensive Part A data readout in Q1 2027. Part A population is expected to be approximately 50/50 split between 'fit' (1L 7+3) and 'unfit' (venetoclax-based) subjects, compared to 70/30 in the first 45 enrolled; blinded data continues to show absence of cardiotoxicity.
Why this rating
Major clinical milestone for a ~$8.8M market-cap company; Part A completion is pivotal for lead program viability and Q1 2027 readout could define company trajectory. Positive enrollment pace and safety signal are encouraging for microcap.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-5.1% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.58 ▲ 2.63% | at our read · unknown $0.57 | +10 min · unknown $0.57 ▼ 0.35% | +30 min pending | +1 hr pending | +4 hrs pending |
The stock had already moved -2.56% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.